Rathbones Group PLC Sells 12,766 Shares of Medtronic PLC $MDT

Rathbones Group PLC reduced its position in Medtronic PLC (NYSE:MDT) by 19.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 52,746 shares of the medical technology company’s stock after selling 12,766 shares during the period. Rathbones Group PLC’s holdings in Medtronic were worth $5,067,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of MDT. Delos Wealth Advisors LLC bought a new stake in shares of Medtronic in the 2nd quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic in the 3rd quarter valued at about $27,000. Lodestone Wealth Management LLC bought a new stake in shares of Medtronic in the 4th quarter valued at about $27,000. Valley Wealth Managers Inc. bought a new stake in shares of Medtronic in the 3rd quarter valued at about $29,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of Medtronic in the 4th quarter valued at about $29,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Stock Down 0.4%

MDT stock opened at $86.27 on Tuesday. The firm has a 50 day moving average of $94.18 and a 200 day moving average of $96.19. The stock has a market capitalization of $110.77 billion, a PE ratio of 24.03, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on MDT shares. Citigroup started coverage on shares of Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price target on the stock. Piper Sandler lowered their price target on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a report on Wednesday, April 1st. Wells Fargo & Company started coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. JPMorgan Chase & Co. lowered their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Finally, CICC Research initiated coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $109.85.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).